Semtech Corporation Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Semtech Corporation Common Stock trades at $154 (market cap $16.12B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Semtech Corporation Common Stock is far larger — about 9× Vir Biotechnology Inc. Common Stock's market cap, and Semtech Corporation Common Stock is more actively traded (3,682,647 versus 1,782,836). Which is the better fit depends on your goals — on Pluang, investors hold Semtech Corporation Common Stock for 2 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SMTC | VIR | |
|---|---|---|
Market Cap | $16.12B | $1.80B |
Volume | 3,682,647 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $197.20 | $11.78 |
52-Week Low | $62.57 | $5.12 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $16.41B | $1.36B |
Signals from Pluang's Aura AI — not financial advice
SMTC trades at $172.78, up 2.67% today, with a bullish technical setup near its pivot point of $173. The stock has gained 154% year-to-date, driven by strong AI data center demand and recent earnings beats. Revenue is projected to grow from $909 million in 2025 to $1.2 billion in 2026, with net income turning positive. Analysts maintain a strong buy consensus with an average price target of $216.38.
Outlook is positive given robust AI-driven growth and expanding partnerships, but high valuation multiples and recent insider selling pose risks. The stock's momentum hinges on continued execution in data center markets and the upcoming Q3 2026 earnings report.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Semtech develops analog and mixed-signal semiconductors and connectivity products. Its technologies are used in communications, data centers, industrial systems, and IoT devices.
Read more on SMTC →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →